Table 1.

Demographics and clinical characteristics of treated patients

Characteristics	Patients (n = 12)
Median age (range), y	63 (34-81)
Male:female	7:5
Infused/enrolled	12/13
ECOG performance status, no. %
0-1	7/12
2+	5/12
Disease location
Parenchymal	11/12
Leptomeningeal  enhancement/CSF+	2/12
Cell of origin
Germinal center B-cell type	1/12
Nongerminal center B-cell  type	11/12
Median no. of previous lines of antineoplastic therapy (range)	4 (2-9)
Prior methotrexate-based regimen
Yes	12/12
No	0/12
Prior thiotepa-based ASCT
Yes	3/12
No	9/12
BTKi refractory
Yes	12/12
No	0/12
IMiD refractory *
Yes	4/12
No	8/12
TEDDI-R refractory
Yes	6/12
No	6/12
Prior radiotherapy
Yes	4/12
No	8/12
Bridging therapy (including high-dose steroids)
Yes	12/12
No	0/12
Median vein-to-vein time, d	33 (27-37)

ECOG, Eastern cooperate oncology group performance status; TEDDI-R, temozolomide, etoposide, Doxil, dexamethasone, ibrutinib, and rituximab.

^*4 patients received IMiD as part of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide.